Hemorrhages among patients treated with low-molecular-weight heparins;Hemorragias en pacientes tratados con heparinas de bajo peso molecular

Revista Clinica Espanola

Volumn 202, Issue 11, 2002, Pages 583-587

  Vallano Ferraz, A ^a,b,c   Pedros Cholvi C ^c   Montane Esteva E ^c   Bejarano Romero, F ^a   Lopez Andres A ^a   Cereza Garcia G ^c   Arnau de Bolos J M ^a,b,c  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c Fundacion Institut Catala de Farmacologia   (Spain)

Author keywords

Fractionated heparins; Hemorrhages; Low molecular weight heparins; Risk factors

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 10A; ENOXAPARIN; NADROPARIN; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; BLEEDING; CHEMICALLY INDUCED DISORDER; FEMALE; HUMAN; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; RISK FACTOR; AGE; BLEEDING DISORDER; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG SURVEILLANCE PROGRAM; FATALITY; GASTROINTESTINAL HEMORRHAGE; HOSPITAL ADMISSION; MEDICAL ASSESSMENT; MEDICAL RECORD; MUSCLE BLEEDING; OUTPATIENT CARE; PATIENT INFORMATION; RISK ASSESSMENT; TEACHING HOSPITAL; TREATMENT PLANNING;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 0036854750     PISSN: 00142565     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2565(02)71153-3     Document Type: Article

References (31)

1. Carter CJ, Kelton JG, Hirsch J, Cerskus A, Santos AV, Gent M. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin. Blood 1982;59:1239-45.
2. Nurmohamed MB, Rosendaal FR, Büller HR, Dekker E, Homes DW, Vandebroucke JP, et al. Low molecular weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992; 340:152-6.
3. Leizorovicz A, Haugh MC, Chapuis FR, Samama MM, Boissel JP. Low molecular weight heparin in prevention of perioperative thrombosis. BMJ 1992;305:913-20.
4. Leizorovicz A, Simonneau G, Decousus H, Boissel JP. Comparison of efficacy and safety of low molecular weights heparins and unfractioned heparin in initial treatment of deep venous thrombosis: an meta-analysis. BMJ 1994;309:299-304.
5. Lensing AW, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med 1995;155:601-7.
6. Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis. Am J Med 1996;100:269-77.
7. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized controlled trials. Ann Intern Med 1999;130:800-9.
8. Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unaswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000;160:181-8.
9. The Columbus Investigators. Low-molecular-weight heparins in the treatment of patients with venous thromboembolism. N Engl J Med 1997; 337:657-62.
10. Simonneau G, Sors H, Charbonnier B, Page Y, Laaban JP, Azarian R, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESSE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. N Engl J Med 1997;337:663-9.
11. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997;337:447-52.
12. Spinler SA, Nawarskas JJ. Low-molecular-weight heparins for acute coronary syndromes. Ann Pharmacother 1998;32:103-10.
13. Metzger G, Gingbart G. Spinal epidural hematoma following epidural anesthesia versus spontaneous spinal subdural hematoma: two cases reports. Acta Anaesthesiol Scand 1991;35:105-7.
14. Vandermeulen EP, van Aken H, Vermylen J. Anticoagulants and spinal-epidural anesthesia. Anesth Analg 1994;79:1165-77.
15. Sternlo JE, Hybbinette CH. Spinal subdural bleeding after attempted epidural and subsequent spinal anaesthesia in a patient on thromboprophylaxis with low molecular weight heparin. Acta Anaesthesiol Scand 1995; 39(4):557-9.
16. Poterfield WR, Wu CL. Epidural hematoma in an ambulatory surgical patient. J Clin Anesth 1997;9(1):74-7.
17. Wysowsky DK, Talarico L, Bacsanyi J, Bostein P. Spinal and epidural hematoma and low-molecular-weight heparin. N Engl J Med 1998;338 (24):1774-5.
18. Landefeld CS, Anderson PA, Goodnough LT, Moir TW, Hom DL, Rosenblatt M, et al. The bleeding severity index. Validation and comparison to other methods for classifying bleeding complications for medical therapy. J Clin Epidemiol 1989;42:711-8.
19. Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood 1991;78(9):2337-43.
20. Bigaroni A, Perrier A, de Moerloose P, Perneger T, Bounameaux H. Risk of major bleeding in unselected patient with venous thromboembolism. Blood Coagul Fibrinolysis 2000;11:199-202.
21. Duglapa BA, Rivers CW, Nutescu E. Dosing and monitoring of low-molecular-weight heparins in special populations. Pharmacotherapy 2001; 218-34.
22. Weitz JL. Low-molecular-weight heparins. N Engl J Med 1997;337: 688-98.
23. Aguilar D, Goldhaber S. Clinical uses of low-molecular-weight heparins. Chest 1999;115:1418-23.
24. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N EngI J Med 1996;334:677-81.
25. Koopman MMW, Prandoni P, Piovella F, Ockelford PA, Brandjes DP, van der Meer J, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital with low-molecular weight heparin administered at home. The Tasman Study Group. N Engl J Med 1996;334:682-7.
26. Manckoundia P, Zaraoula B, Lalu-Fraise A, Bessencenot JF, Lorcerie B, Pfitzenmeyer P. Muscle hematoma in the very elderly receiving low-molecular weight heparins. Presse Med 2000;29:702.
27. Morau D, Barthelet Y, Spilmann E, d'Athis F. Hematoma of the right rectus abdominis in relation to treatment with low-molecular-weight heparin. Ann Fr Anesth Reanim 2000;19:60-70.
28. Montoya JP, Pokala N. Retroperitoneal hematoma and enoxaparin. Ann Intern Med 1999;131:796-7.
29. Dickinson LD, Miller LD, Patel CP, Gupta SK. Enoxaparin increases the incidence of postoperative intracraneal hemorrhage when initiated preoperatively for deep venous thrombosis prophylaxis in patients with brain tumors. Neurosurgery 1998;43(5):1074-81.
30. Wong JS. Spontaneous suprachoroidal haemorrhage in a patient receiving low-molecular-weight heparin (fraxiparine) therapy. Aust N Z J Ophthalmol 1999;27:433-4.
31. Zidane M, Schram MT, Planken EW, Molendijk MD, Rosendaal FR, van der Meer FJM, et al. Frequency of major hemorrhage in patients treated with unfractionated intravenous heparin for deep venous thrombosis or pulmonary embolism. A study in routine clinical practice. Arch Intern Med 2000;160:2369-73.